25.01.2012

Qiagen to Provide siRNA Libraries in Labcyte Acoustically Compatible Microplates

Qiagen and Labcyte, the developer of acoustic liquid handling, announced that Qiagen FlexiPlate siRNA reagent libraries are now available in Labcyte Echo qualified microplates. These microplates enable researchers to use the Echo liquid handler to miniaturize the transfer of small interfering RNA reagents. more27.07.2011

Multiplex PCR Plus Kit by Qiagen

Qiagen has launched the Multiplex PCR Plus Kit, designed for rapid and sensitive multiplex PCR that allows researchers to amplify several targets in one PCR run. The kit provides fast reaction times and comes with a pre-optimized protocol, eliminating the need for optimization and delivering reliable results on the first attempt. more25.05.2011

Mutation Profiling by Qiagen's qBiomarker Somatic Mutation PCR Array System

Qiagen launches the qBiomarker Somatic Mutation PCR Array System, designed for rapid and accurate mutation profiling in basic research and drug discovery. The assays consist of collections of pathway or cancer-specific assays in 96- or 384-well plate formats with a number of pathways (EGFR, ErbB2, etc.) and cancer types. more10.03.2011

Vera Kallmeyer and Elizabeth E. Tallett

Dr. Vera Kallmeyer, M.D., Ph.D., and Elizabeth E. Tallett - QIAGEN announced the proposal of these two international leaders in life sciences and healthcare for election to its Supervisory Board. The Supervisory Board will propose these two independent candidates based on their extensive experience in the life sciences and healthcare industries as well as their roles as directors and officers in various international companies. more02.03.2011

Qiagen and Epigenomics Sign Collaboration Agreement

Qiagen and Epigenomics, the cancer molecular diagnostics company announced that the companies have entered into an option agreement allowing Qiagen to develop and, should Qiagen exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies. Read more about the terms of the agreement. more12.01.2011

Qiagen to Acquire Stake in Alacris

Qiagen to acquire stake in Alacris, gaining access to biomarker pipeline for use in personalized healthcare assays. Alacris Theranostics is a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile. Qiagen will have an exclusive option to access all biomarkers emerging from this discovery program. more17.11.2010

iPhone and iPad App

Qiagen launched the free Qiagen App, an application that can be used on iPhone and iPad mobile devices with tables of commonly used lab buffers and solutions as well as a variety of conversion and dilution calculators, all aimed at easing scientists' daily work. more14.10.2010

Agreement on Molecular Tests for HIV, HCV and HPV

Qiagen and Abbott announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed. more08.10.2010

Automated Workflow System for Molecular Diagnostics

QIAsymphony RGQ is a flexible automated solution for molecular testing and incorporates all workflow steps from sample to detection. It offers many features which create exceptional flexibility, such as continuous loading, random access, open channels for user-developed tests, the broadest menu of commercial assays as well as the ability to process an almost unlimited range of sample types. QIAsymphony thus provides laboratories with a system that transforms their work in the emerging field of molecular diagnostics. more04.10.2010

Tests for Companion Diagnostics

Qiagen announced the launch of several tests for cancer companion diagnostics, CE-marked with the Rotor-Gene Q thermocycler (EGFR) and the PyroMark pyrosequencing system (EGFR, NRAS, KRAS, BRAF). The new tests are used in personalized healthcare of cancer by identifying certain mutations in these particular genes, which then help clinicians to select and tailor the most appropriate treatment. more